Lost your password?
Don't have an account? Sign Up

Chengdu Kanghong Pharmaceutical Group is a China-based company principally engaged in research, development, manufacturing and distribution of Chinese patent medicines, chemical drugs and biological products.

Among the Company’s main product is the Conbercept Ophthalmic Injection for treating wet AMD. The Company distributes its products in the Chinese domestic market and is currently undertaking a large multicenter study by the name of “Panda trial”, with the aim of securing the CE and FDA approvals for its flagship product.

Kanghong has acquired IOPtima in November 2017.

Read on Eyewire Today